Tamoxifen response in breast cancer predicted by protein marker
the ONA take:
An abnormally low amount of the protein TGFBR2 is associated with resistance to tamoxifen response in breast cancer treatment, according to a study published in Cancer Research.
“Our data indicate that TGFBR2, which detects TGF-beta and thereby activates subsequent cellular responses, could be used as a marker in the clinics to identify patient subgroups that may not benefit from hormone therapy alone and may require additional therapies,” said author Susann Busch, PhD, of Gothenburg University.
Dr. Busch and colleagues analyzed tumor samples of 564 pre-menopausal women who were enrolled in clinical trials from 1986 to 1991 and randomly assigned to either tamoxifen for two years (276) or no systemic treatment (288).
They found that among women who received tamoxifen and had estrogen receptor-positive tumors, those who had low TGFBR2 levels had a 73 percent lower recurrence-free survival rate compared to those with high levels of the protein.
In a follow-up series of laboratory experiments, the same researchers found that, in a drug-resistant cell line, there were low levels of TGFBR2 and abnormal pathway activation.
An abnormally low amount of the protein TGFBR2 is associated with resistance to tamoxifen response in breast cancer treatment.
- Compound in Teas, Peas, Soybeans May Increases Prostate Cancer Risk
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer
- Duloxetine May Improve AI-Associated Joint Pain in Early Stage Breast Cancer
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- Vitamin D Supplementation is Recommended for Pediatric Patients With Sarcoma
- Extended Adjuvant Therapy for Breast Cancer Improves 5-Year Disease-free Survival
- A Structured Group Exercise Program for Patients With Metastatic Cancer Receiving Chemotherapy and CTNNB1 (β-catenin) as a Biomarker of Exercise Efficacy
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|